Trial Profile
An Open-Label Taste Assessment of BMS-986165 in Healthy Participants
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Sep 2019
Price :
$35
*
At a glance
- Drugs Deucravacitinib (Primary)
- Indications Autoimmune disorders; Crohn's disease; Inflammatory bowel diseases; Plaque psoriasis; Psoriasis; Psoriatic arthritis; Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 26 Sep 2019 Status changed from recruiting to completed.
- 28 Nov 2018 New trial record